Updated data from the pivotal phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall surviva ...

Basel, 20 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) discussed the supplemental Biologics ...

Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.

Genentech, a biotechnology company and member of the Roche Group, announced on May 12, 2025, that it will invest more than $700 million in a new, state-of-the-art drug manufacturing facility in Holly ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today plans to invest more than $700 million in a new 700,000 square ...

Genentech, in the United States ... in collaboration with AbbVie, Hemlibra® (emicizumab), PiaSky® (crovalimab), Lunsumio® (mosunetuzumab) and Columvi® (glofitamab). Our pipeline of investigational ...

and PiaSky (Genentech/Roche), offering new mechanisms for treatment. In just over a year, Fabhalta has gained substantial traction, with physician consideration for first-line use doubling year ...

You may also report side effects to Genentech at (888) 835-2555. PiaSky® is a prescription medicine used to treat a disease called paroxysmal nocturnal hemoglobinuria (PNH) in adults and children ...

– Gazyva is the only anti-CD20 monoclonal antibody in a randomized Phase III study to demonstrate a complete renal response benefit – – The filing application is based on data from the Phase III ...

Roche’s RHHBY member company, Genentech, announced the FDA approval ... in 2024 — Itovebi for a hard-to-treat breast cancer and PiaSky for a serious blood disorder. However, pipeline setbacks ...

It is jointly commercialised by AbbVie and Genentech, a member of the Roche Group ... Hemlibra® (emicizumab), PiaSky® (crovalimab), Lunsumio® (mosunetuzumab) and Columvi® (glofitamab). Our pipeline of ...